Pyrimidopyridone and pteridone derivatives as inhibitors of the gcn2 kinase, compositions and uses thereof
EP4771009A1Pending Publication Date: 2026-07-08ONTARIO INST FOR CANCER RES OICR +1
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- ONTARIO INST FOR CANCER RES OICR
- Filing Date
- 2024-08-29
- Publication Date
- 2026-07-08
AI Technical Summary
Technical Problem
There is a need for potent and selective inhibitors of the general control nonderepressible 2 (GCN2) kinase to treat cancers and peripheral neuropathies, as existing small molecule inhibitors have limitations in efficacy and specificity.
Method used
Development of novel pyrimidopyridone and pteridone derivatives that act as inhibitors of the GCN2 kinase, offering a potential therapeutic approach for treating diseases associated with GCN2 activity.
Benefits of technology
The described compounds effectively inhibit GCN2 kinase activity, providing a promising therapeutic strategy for treating cancers and peripheral neuropathies, including Charcot-Marie-Tooth disease, by disrupting the GCN2-mediated integrated stress response pathway.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CA2024051124_06032025_PF_FP_ABST
Abstract
The present application relates to pyrimidopyridone and pteridone compounds of Formula I, to processes for their preparation and to compositions comprising them More particularly, the present application relates to compound of Formula I that have activity as inhibitors of the general control nonderepressible 2 (GCN2) kinase and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting GCN2 kinase such as cancers and neuronal diseases.
Need to check novelty before this filing date? Find Prior Art